Ludwig Institute for Cancer Research Limited

Amrad Corporation Limited

The Walter and Eliza Hall Institute of Medical Research

Immulogic Pharmaceutical Corporation

Immulogic Pharmaceuticals, Inc.

Other

The Heart Research Institute Ltd.

Richard John Simpson

Nicos Anthony Nicola

Donald Metcalf

Wayne Robert Thomas

Douglas James Hilton

Antony Wilks Burgess

Tracy Ann Willson

Keven J Turner

Geoffrey Alexander Stewart

David P Gearing

Nicholas Martin Gough

Edouard C Nice

Jacques Van Snick

Catherine Uyttenhove

Andrew W Boyd

Edouard Collins Nice

Geoffrey Stephen Begg

Julie A King

David Wilkinson

Larry David Ward

Lloyd J Old

Gerd J Ritter

Sydney Welt

Julie Ann King

Ian Wicks

Sara J White

Joan K Heath

Cameron Johnstone

Hong Ji

R L Moritz

Manuel Baca

Sandra Elaine Nicholson

Warren S Alexander

Simon Foote

Anthony W Burgess

Jian-Guo Zhang

Ian Peter Wicks

Alison Farley

Meredith Jane Layton

Colleen Elso

Gavin Reid

Robert James

Robert H Whitehead

Robert L Moritz

Martin Lackmann

Carolyn Geczy

B Catimel

Kaw-Yan Chua

Bruno Catimel

The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associated therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signalling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.

Screening methods using SOCS box-containing peptides

A method of detecting a mutation or a difference of one or more nucleotides between a nucleic acid molecule to be tested and a reference nucleic acid molecule, said method comprising subjecting the test nucleic acid molecule to base specific cleavage to generate oligonucleotide fragments, separating the resulting oligonucleotide fragments based on mass by MALDI-ATOF MS and/or other equivalent procedure to produce a fingerprint of then oligonucleotide fragments comprising one or more peaks wherein a peak represents the mass of each fragment and identifying an altered peak relative to a reference nucleic acid molecule subjected to the same procedure wherein the presence of an altered peak is indicative of a difference of one or more nucleotides in said tested nucleic acid molecule.

Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage

The present invention relates to a method of screening for ligands to a receptor-type tyrosine kinase. The receptor-type tyrosine, in its naturally occurring form, is characterized by being reactive to monoclonal antibody III.A4, having an apparent molecular weight of approximately 120-150 kD in its glycosylated form, and having the N-terminal amino acid sequence E L I P Q P.

Method for screening for soluble ligands to a receptor-type tyrosine kinase

The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro to a greater extent when compared to its ability to inhibit LIF from said first mammalian species.

Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)

This invention relates to isolated proteins and to peptides which are found on the surface of colon cells and colon cancer cells, as well as to nucleic acid molecules encoding said protein and peptides. The protein and peptides bind to tumor associated antibodies, such as mAb 33. The monomeric protein has a molecular weight of about 43 kD as determined by SDS gel electrophoresis under non-reducing conditions. In addition, this invention relates to the use of said nucleic acid molecules, protein, in monomeric or multimeric form, and to antibodies to said peptides in diagnostic, screening and therapeutic methods. This invention further relates to antibodies specific for said protein, in monomeric or multimeric form, and to antibodies to said peptides.

Isolated nucleic acid which encodes protein which binds to A33 antibody

The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA and suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

Leukaemia inhibitory factor

Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.

Cloning and sequencing of allergens of dermatophagoides (house dust mite)

Isolated peptides comprising at least one epitope, such as a T or B cell epitope, of the Group II proteine allergen from Dermatophagoides, Der p II, are disclosed. Also disclosed are therapeutic compositions containing one or more such peptides, and therapeutic methods of using such peptides. Also disclosed are diagnostic compositions containg one or more such peptides, and dianostic methods of using such peptides.

Cloning of mite allergens

Isolated allergens of Dermatophagoides (house dust mites) particularly of the species and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In addition, the or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.

Recombinant DNA expression vectors or cloning vehicles capable of expressing a polypeptide displaying the antigenicity of an allergen of house dust mites of the genus Dermatophagoides. A synthetic protein or polypeptide displaying antigenicity of all or a portion of an allergen of house dust mites of the genus Dermatophagoides. Methods of diagnosing and treating such allergies.

The present invention relates to an isolated receptor-type tyrosine kinase. The receptor-type tyrosine, in its naturally occurring form, is characterized by being reactive to monoclonal antibody III.A4, having an apparent molecular weight of approximately 120-150 kD in its glycosylated form, and having the N-terminal amino acid sequence E L I P Q P.

Receptor-type tyrosine kinase and use thereof

Recombinant DNA expression vectors or cloning vehicles capable of expressing a polypeptide displaying the antigenicity of an allergen of house dust mites of the genus Dermatophagoides. A synthetic protein or polypeptide displaying the antigenicity of all or a portion of an allergen of house dust mites of the genus Dermatophagoides. Methods of diagnosing and treating such allergies.

Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagiodes pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p II. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.

A first reactant is immobilized i.e. in a porous matrix (50), adjacent a sample electrode (46) within a reaction chamber. Energizing of the electrode (46) electrophoretically attracts a mobile second reactant and/or electrolytically induces appropriate reaction conditions to enhance reaction of the first and second reactants. Polarity reversals between the sample electrode (46) and remote electrodes (38), (42), (44) cause unreacted second reactant and/or by-products to migrate away from the immobilized first reactant. The techniques are useful for sequential chemical reactions such as sequencing or construction of proteins, polysaccharides and nucleic acids where cyclical additions and removals of reactants are required. The techniques are amenable to automated micro and nano scale construction and operation and allow direct electrophoretic (38) interfacing with chromatographic, HPCE and mass spectrophotometric equipment.

Apparatus allowing sequential chemical reactions

The present invention provides isolated DNA molecules encoding human and murine LIF, and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

Growing community of inventors

Richmond, Australia

Richard John Simpson